Binhui Biopharmaceutical Co., Ltd.
16
8
8
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
25.0%
4 terminated/withdrawn out of 16 trials
0.0%
-86.5% vs industry average
6%
1 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors
Role: lead
oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection
Role: lead
OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer
Role: lead
Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years
Role: lead
OH2 Injection in Melanoma
Role: lead
OH2 Oncolytic Viral Therapy in Central Nervous System Tumors
Role: lead
OH2 Injection in Solid Tumors
Role: lead
OH2 Injection in Combination With HX008 for Melanoma.
Role: lead
OH2 Administered by Intratumoral Injection
Role: lead
OH2 Oncolytic Viral Therapy in Solid Tumors
Role: lead
OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer
Role: lead
OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer
Role: lead
First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer
Role: lead
OH2 Oncolytic Viral Therapy in Pancreatic Cancer
Role: lead
First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer
Role: collaborator
Safety and Efficacy Study of Virus Activated Killer Immune Cells (VAK) for Malignant Pleural and Peritoneal Effusion
Role: collaborator
All 16 trials loaded